Press Releases

Date	Title	Company
18-Oct-2023	Brain Implants Market Sets New Record, Projected at USD 4.5 billion by 2032 at 12.2% CAGR	The Wire Times
18-Oct-2023	Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million	Xlife Sciences AG
18-Oct-2023	Semen Analysis Market Sets New Record, Projected at USD 1.49 Billion by 2031 at 4.5% CAGR	The Wire Times
18-Oct-2023	Oral Cancer Treatment Market Expected to Reach $2.7 Billion by 2030 \| Current Trends and Industry Analysis	The Wire Times
18-Oct-2023	Cardiovascular Diagnostic Testing Market Expected to Reach $15.4 Billion by 2030 \| Big Corps Trends and Strategy Analysis	The Wire Times
18-Oct-2023	Healthcare Fraud Detection Market Update 2023 : Anticipated to Hit USD 3.6 Billion by 2031 \| 12.6% CAGR 2022 to 2031	The Wire Times
17-Oct-2023	Incontinentia Pigmenti Treatment Market is Projected to Reach at a CAGR of 5.20% By 2029	The Wire Times
17-Oct-2023	Empaveli is the first treatment for PNH that binds to the complement protein C3.	Businesswire
17-Oct-2023	Praxis Medical Announces FDA Clearance of the EndoCore EBUS-TBNA Biopsy Device	Businesswire
17-Oct-2023	Sialolithiasis Treatment Market to Observe Prominent Growth Potential of 4.70% by 2029	The Wire Times
17-Oct-2023	Resumen: El estudio UNITE de fase IV de Teva demuestra que AJOVY® (fremanezumab) redujo los ataques de migraña y los síntomas de depresión en personas con migraña y trastorno depresivo mayor	Businesswire
17-Oct-2023	L’étude de phase IV UNITE de Teva montre qu’AJOVY® (fremanezumab) réduit les crises de migraine et les symptômes de dépression chez les personnes migraineuses souffrant d’un trouble dépressif majeur	Businesswire
17-Oct-2023	Riassunto: Lo studio UNITE di fase IV di Teva dimostra che AJOVY®(fremanezumab) ha contribuito a ridurre gli attacchi di emicrania e i sintomi depressivi nei soggetti affetti da emicrania con disturbo depressivo maggiore	Businesswire
17-Oct-2023	Teva UNITE-Studie der Phase IV zeigt: AJOVY® (fremanezumab) reduzierte Migräne-Anfälle und depressive Symptome bei Migräne-Patienten mit schwerer depressiver Störung	Businesswire
17-Oct-2023	Samenvatting: Fase IV UNITE-studie van Teva toont aan dat AJOVY® (fremanezumab) migraineaanvallen en depressiesymptomen vermindert bij mensen die aan migraine lijden met belangrijke depressieve stoornissen	Businesswire
17-Oct-2023	First Results of Median Technologies’ iBiopsy® HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress (Oct 20-24, 2023, Madrid, Spain)	Businesswire
17-Oct-2023	Announcing Aptyx: New Brand Brings Together Market-Leading Molding, Extrusion, Coatings, and Assembly Capabilities	Businesswire
17-Oct-2023	LG Chem Announces Initiation of Two Phase 2 Trials (ROUTE & SIGNAL) of Novel Oral MC4R Agonist LB54640 in Patients with Rare Forms of Genetic Obesity	Businesswire
17-Oct-2023	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of R1 RCM Inc. (RCM) on Behalf of Investors	Businesswire
17-Oct-2023	Next Generation Drug Conjugates Market to Soar with Over 20% CAGR: Revolutionizing Rare Disease Treatment and Oncology Therapies - ResearchAndMarkets.com	Businesswire